Buxofeb 40 is a xanthine oxidase inhibitor formulation developed to support the management of hyperuricemia associated with gout.
The formulation assists healthcare professionals in reducing uric acid levels and supporting long-term management of gout-related conditions during physician-directed therapy.
Category : Tablets & Capsules
Get a QuoteDescription
Buxofeb 40 contains Febuxostat, a selective xanthine oxidase inhibitor used in the management of elevated uric acid levels in patients with gout.
Febuxostat works by inhibiting the xanthine oxidase enzyme responsible for uric acid production, helping reduce serum uric acid levels and preventing urate crystal formation.
The formulation is designed to assist in maintaining controlled uric acid levels and supporting long-term gout management under medical supervision.
Composition
Febuxostat 40 mg Tablets
Intended Use
Treatment should be based on clinical evaluation and prescribed by a registered healthcare professional.
| Property | Details |
|---|---|
| Dosage Form: | Tablet |
| Therapeutic Category: | Anti-Gout / Xanthine Oxidase Inhibitor |
| Pack Size: | 10 × 10 Alu-Alu |
| Route of Administration: | Oral |
| Brand: | Servochem |
